CVS Health stock closed at US$99.13, down just over 5% on the day, even though the headline numbers landed solidly in the green. The company reported Q2 2026 revenue of about US$105.5b and basic earnings per share of roughly US$2.33, alongside raised full year guidance that points to higher adjusted earnings and cash generation than previously expected.

The gap between a weaker share price and a stronger profit and guidance story is what matters for long term investors. The rest of this earnings breakdown will focus on whether those upgraded targets and margin trends are enough to support a multi year case for CVS Health.

Is CVS Health a rare case where a weak share price and high trailing P/E signal a value trap, or a misread on future…